Emcure Pharmaceuticals Limited (EMCURE) reported revenue of ₹2,580 Cr and net profit of ₹292 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.
EMCURE fundamentals, Fundamental score 88/100
The statements below are read from Emcure Pharmaceuticals Limited’s filed results, 13 filed quarters and 8 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q1 FY26-27 · filed Aug 7, 2026 · audited
Sales CAGR · 3Y+15.4%FY22 → FY25
Sales CAGR · 4Y+12.0%FY21 → FY25
PAT CAGR · 3Y+18.8%FY22 → FY25
PAT CAGR · 4Y+7.6%FY21 → FY25
Price · 1Y+40.6%EOD
Price CAGR · 3Y—EOD
Quarterly resultsConsolidated
₹ Cr
Jun2023
Sep2023
Dec2023
Mar2024
Jun2024
Sep2024
Dec2024
Mar2025
Jun2025
Sep2025
Dec2025
Mar2026
Jun2026Latest
YoYlatest
Sales
1,556
1,663
1,668
1,771
1,815
2,002
1,963
2,116
2,101
2,270
2,363
2,470
2,580
+22.8%
1,261
1,334
1,374
1,460
1,478
1,621
1,608
1,714
1,684
1,794
1,871
1,990
2,048
+21.6%
Operating profit
295
329
294
311
337
381
355
402
417
475
493
480
532
+27.8%
OPM %
19.0%
19.8%
17.6%
17.6%
18.6%
19.0%
18.1%
19.0%
19.8%
20.9%
20.8%
19.4%
20.6%
+0.8 pp
Other income
15.0
-2.00
22.0
11.7
23.4
36.0
3.90
4.45
3.70
3.12
1.85
3.99
2.07
-44.0%
Interest
52.0
59.0
61.0
65.0
59.0
46.0
31.8
39.0
26.8
32.5
38.0
46.4
31.5
+17.9%
Depreciation
67.0
70.0
84.0
91.0
94.0
97.0
96.8
96.8
99.5
105
105
106
110
+10.1%
Profit before tax
191
198
171
167
207
273
230
261
291
341
314
341
394
+35.3%
Tax %
26.3%
26.3%
29.8%
27.5%
26.4%
26.0%
32.1%
24.3%
26.1%
26.4%
26.3%
28.6%
25.7%
-0.5 pp
Net profit
141
146
120
121
153
202
156
197
215
251
231
244
292
+36.2%
EPS (₹)
7.21
7.69
6.27
6.36
7.95
10.29
8.12
9.97
10.92
12.85
12.16
12.84
15.50
+41.9%
One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split↔ scroll for earlier quarters
Revenue & net profit trend
last 13 quarters
RevenueNet profit
Revenue & net profit — Consolidated13 quarters
Segment results
Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.
Forensic checksauto-scanned from the filing
Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.
How results moved the priceEOD reaction on the session the market could trade the filing
Avg absolute result-day move ±2.9%· EPS surprise: no estimates source· 4 earlier quarters have no dated filing on record
Q1'27filed Thu 6 Aug 13:42 · traded that sessiongap +0.5%close −1.1%
Q4'26filed Tue 5 May 19:42 · first tradeable session Wed 6 Maygap +0.9%close −1.8%
Q3'26filed Wed 4 Feb 14:46 · traded that sessiongap +0.1%close +1.9%
Q2'26filed Tue 11 Nov 13:35 · traded that sessiongap +0.3%close −4.0%
Q1'26filed Thu 7 Aug 13:42 · traded that sessiongap −1.2%close −1.5%
Q4'25filed Thu 22 May 14:49 · traded that sessiongap +1.5%close +8.8%
Q3'25filed Thu 6 Feb 15:04 · traded that sessiongap +0.5%close +2.8%
Q2'25filed Thu 7 Nov 15:41 · first tradeable session Fri 8 Novgap +3.4%close −3.2%
Q1'25filed Tue 13 Aug 21:13 · first tradeable session Wed 14 Auggap +2.1%close +0.5%
